MedTrace Logo

Frequency of SPAD in Adult Patients

NCT05664035 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 99

Last updated 2026-05-18

No results posted yet for this study

Summary

The DETECT study aims to demonstrate the importance of detecting SPAD in adult patients with recurrent benign and/or severe unexplained bacterial upper/lower respiratory tract infections. Unlike children in whom the deficit may be transient, long-term strategies are warranted in SPAD adult patients to prevent severe infections and lung disability. Beyond the diagnosis of this still unrecognized PID in adult patients, the investigators want to assess the impact of prophylactic antibiotics or IgRT on infections prevention and on quality of life in adult patients with the most severe clinical phenotypes, recurrent infections with high frequency of antibiotics take and/or recurrent infections with complications like bronchiectasis and/or severe infections requiring hospitalizations.

Conditions

  • Specific Antibody Deficiency
  • Predominantly Antibody Deficiencies

Interventions

BIOLOGICAL

Diagnosis of SPAD using immunization with PPV23

Diagnosis of SPAD using immunization with PPV23

Sponsors & Collaborators

  • French Healthcare network for rare immune and hematological disorders (MARIH)

    collaborator UNKNOWN

  • Takeda

    collaborator INDUSTRY

  • VitalAire

    collaborator INDUSTRY

  • Laboratoire français de Fractionnement et de Biotechnologies

    collaborator INDUSTRY

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Guillaume LEFEVRE, MD,PhD · University Hospital, Lille

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05664035 on ClinicalTrials.gov